Copertina

Editorial: Linking Patients With Cirrhosis to Clinical Care—The Hurdles and Way Forward

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jimmy Che‐To Lai, Junlong Dai
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
di: Mary Yue Wang, et al.
Pubblicazione: (2026)

Barriers to Medical Care Are Frequently Reported by Patients With Cirrhosis
di: William Chai, et al.
Pubblicazione: (2025)

Editorial: Non‐selective beta‐blockers: A lifesaving shield for critically ill patients with acute decompensation of cirrhosis?
di: Ling Yang, et al.
Pubblicazione: (2024)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
di: Mary Yue Wang, et al.
Pubblicazione: (2025)

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
di: Yuki Utakata, et al.
Pubblicazione: (2026)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
di: Shuai Xia, et al.
Pubblicazione: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation
di: Thanawin Pramotedham, et al.
Pubblicazione: (2026)

Editorial: Timely Follow‐Up in Cirrhosis: How Does It Work?
di: Nina Kimer, et al.
Pubblicazione: (2024)

Systematic Review: Imaging‐Based Morphological Criteria for Liver Cirrhosis—A Call to Standardise
di: Mei Chin Lim, et al.
Pubblicazione: (2026)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
di: Zhanbo Qu
Pubblicazione: (2026)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
di: Yu Shi, et al.
Pubblicazione: (2025)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
di: Emily Stephenson, et al.
Pubblicazione: (2026)

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis
di: Supachaya Sriphoosanaphan, et al.
Pubblicazione: (2025)

Mortality of Acute Kidney Injury in Cirrhosis: A Systematic Review and Meta‐Analysis of Over 5 Million Patients Across Different Clinical Settings
di: Vasileios Lekakis, et al.
Pubblicazione: (2024)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
di: Sai Kiran Kuchana, et al.
Pubblicazione: (2026)

Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation
di: Lucie Simonis, et al.
Pubblicazione: (2025)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
di: Lucie Simonis, et al.
Pubblicazione: (2025)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
di: Eduardo Vilar‐Gomez, et al.
Pubblicazione: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
di: Christian Labenz, et al.
Pubblicazione: (2026)

Emerging Trends in Patients Hospitalised With Cirrhosis—Aetiologies, Complications and Outcomes Compared to Other Chronic Health Conditions
di: Julian Pohl, et al.
Pubblicazione: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis
di: Stephanie Tsai, et al.
Pubblicazione: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue?
di: Louise J. M. Alferink, et al.
Pubblicazione: (2024)

Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
di: Bernardo de Faria Moraes, et al.
Pubblicazione: (2026)

Correction to ‘Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon’
Pubblicazione: (2025)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
di: Luis Calzadilla Bertot, et al.
Pubblicazione: (2025)

Editorial: Decoding Gut Failure in Cirrhosis—Villin‐1 and the Emergence of a Seventh Organ Failure. Authors' Reply
di: David Tornai, et al.
Pubblicazione: (2026)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis. Authors' Reply
di: Bingqiong Wang, et al.
Pubblicazione: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
di: Ting Wang, et al.
Pubblicazione: (2024)

Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis
di: Deliang Huang, et al.
Pubblicazione: (2026)

Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study
di: Adriana Palom, et al.
Pubblicazione: (2026)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity?
di: Xiao‐Dong Zhou, et al.
Pubblicazione: (2025)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter
di: Anish J. Kuriakose Kuzhiyanjal, et al.
Pubblicazione: (2025)

Timely Follow‐Up After a First Diagnosis of Cirrhosis is Associated With Reduced Mortality but No Impact on Rehospitalisations: A Population‐Based Cohort of 8852 Patients
di: Max S. Schechter, et al.
Pubblicazione: (2024)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
di: Mo‐Yao Tan, et al.
Pubblicazione: (2024)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
di: Yuki Utakata, et al.
Pubblicazione: (2026)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
di: Eric Lawitz, et al.
Pubblicazione: (2025)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
di: Luisa Bertin, et al.
Pubblicazione: (2026)

Editorial: Cholestasis Is an Important Marker for Evaluating Clinical Outcomes and Prognosis in Severe Burns and Critically Ill Patients
di: Andrew T. Roberts, et al.
Pubblicazione: (2026)

Editorial: Clinical Impact of Lipid Profile Change After DAA Treatment in CHC Patients—Authors' Reply
di: Zahra Sarrafan‐Chaharsoughi, et al.
Pubblicazione: (2025)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
di: Yee Hui Yeo, et al.
Pubblicazione: (2026)